Cosi Cristina, Waget Aurelie, Rollet Karin, Tesori Valentina, Newman-Tancredi Adrian
Division de Neurobiologie II, Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin, 81106 Castres, France.
Brain Res. 2005 May 10;1043(1-2):32-41. doi: 10.1016/j.brainres.2005.02.072.
Excessive activation of non-NMDA receptors, AMPA and kainate, contributes to neuronal degeneration in acute and progressive pathologies, possibly including schizophrenia. Because 5-HT(1A) receptor agonists have neuroprotective properties (e.g., against NMDA-induced neurotoxicity), we compared the effects of the antipsychotics, clozapine, ziprasidone and aripiprazole, that are partial agonists at 5-HT(1A) receptor, with those of haloperidol, which is devoid of 5-HT(1A) agonist properties, on kainic acid (KA)-induced striatal lesion volumes, in C57Bl/6N mice. The involvement of 5-HT(1A) receptors was determined by antagonist studies with WAY100635, and data were compared with those obtained using the potent and high efficacy 5-HT(1A) receptor agonist, F13714. Intra-striatal KA lesioning and measurement of lesion volumes using cresyl violet staining were carried out at 48 h after surgery. F13714, antipsychotics or vehicle were administered ip twice, 30 min before and 3 1/2 h after KA injection. WAY100635 (0.63 mg/kg) or vehicle were given sc 30 min before each drug injection. Clozapine (2 x 10 mg/kg), ziprasidone (2 x 20 mg/kg) and aripiprazole (2 x 10 mg/kg) decreased lesion volume by 61%, 59% and 73%, respectively. WAY100635 antagonized the effect of ziprasidone and of aripiprazole but only slightly attenuated that of clozapine. In contrast, haloperidol (2 x 0.16 mg/kg) did not affect KA-induced lesion volume. F13714 dose-dependently decreased lesion volume. The 61% decrease of lesion volume obtained with F13714 (2 x 0.63 mg/kg) was antagonized by WAY100635. WAY100635 alone did not affect lesion volume. These results show that 5-HT(1A) receptor activation protects against KA-induced striatal lesions and indicate that some atypical antipsychotic agents with 5-HT(1A) agonist properties may protect against excitotoxic injury, in vivo.
非NMDA受体(AMPA和海人酸受体)的过度激活会导致急性和进行性病变中的神经元退化,可能包括精神分裂症。由于5-HT(1A)受体激动剂具有神经保护特性(例如,对抗NMDA诱导的神经毒性),我们比较了作为5-HT(1A)受体部分激动剂的抗精神病药物氯氮平、齐拉西酮和阿立哌唑,与缺乏5-HT(1A)激动剂特性的氟哌啶醇,对C57Bl/6N小鼠中 kainic acid(KA)诱导的纹状体损伤体积的影响。通过使用 WAY100635进行拮抗剂研究来确定5-HT(1A)受体的参与情况,并将数据与使用强效且高效的5-HT(1A)受体激动剂F13714获得的数据进行比较。在手术后48小时进行纹状体内KA损伤并使用甲酚紫染色测量损伤体积。F13714、抗精神病药物或赋形剂在KA注射前30分钟和注射后3.5小时腹腔注射两次。WAY100635(0.63 mg/kg)或赋形剂在每次药物注射前30分钟皮下注射。氯氮平(2×10 mg/kg)、齐拉西酮(2×20 mg/kg)和阿立哌唑(2×10 mg/kg)分别使损伤体积减少了61%、59%和73%。WAY100635拮抗了齐拉西酮和阿立哌唑的作用,但仅略微减弱了氯氮平的作用。相比之下,氟哌啶醇(2×0.16 mg/kg)不影响KA诱导的损伤体积。F13714剂量依赖性地减少损伤体积。WAY100635拮抗了F13714(2×0.63 mg/kg)使损伤体积减少61%的作用。单独使用WAY100635不影响损伤体积。这些结果表明,5-HT(IA)受体激活可保护免受KA诱导的纹状体损伤,并表明一些具有5-HT(1A)激动剂特性的非典型抗精神病药物在体内可能保护免受兴奋性毒性损伤。